Overall, these studies have shown little promise for the utility of IL-6 pathway inhibition as a standalone treatment for ovarian cancer, while supporting the possibility that combination regimens may be a fertile area for future investigation. The gene discussed is IL6; the disease is ovarian carcinoma.